They are slaughtering BTG in the dose sales and consultant Comms...

First 34 Last

Share
Profile

Follow
JCoure

41,395 Posts.

1092

18/01/18

09:03

Post #: 30390705
Share

Originally posted by cafa ↑

If the annual number comes in at the higher end, of around $85m, then the PE is 13.x.

I would have thought that this is a tad too low. As we have seen yesterday, any +ve news that could impact dose sales will bounce the SP upwards.

Confirmation of the RHS story from Ricky, and, or from RESIN would be a kicker in my book.

An NCCN recommendation to seperate treatment based on the source would be a bigger kicker, and I believe this is in progress. However they do not work in CAFA time scales

With both, I could see the SP going to the mid to high 20s as there would be a rerating of the the stock with the expected PE going back to the high teens, or even the 20s.

When the FDA give SRX the PMA extension for HCC, or better pan-liver, again we will see a rerating of the stock.

Can they make the $85m number? My view is that with a new senior management team they would be most foolish to put their balls on the line with a number they can't meet, assuming no black swan events.

Thus I conclude that the forward PE of less than 14, allows for some more upward movement in the SP. It will one most interesting to see which analyst comes out with the first report, or maybe we will have to wait until the results are published in 5 weeks time.

Expand

They are slaughtering BTG in the dose sales and consultant Comms space, marketing budget looks down as well, I wonder how they r doing it, looks pretty fabulous.

Market is obviously a little sceptical of management assertions, did the governance folk have a look behind the numbers? Have they hired any governance folk or is that a question the answer is beyond the capability of management?

SRX Price at posting: $17.83 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

DMP

Is Domino's a steal after -25% plunge?

AII

Inside the Depths of Panasqueira: A Legacy Carved in Rock

NMG

New Murchison Gold blasts off at Crown Prince as 'better than expected' results return

THL

Tourism Holdings says Liberation Day tariffs smashed US RV demand

KGD

Kula picks up unexplored niobium play in Malawi, with surface samples logged

OSL

OncoSil wraps up recruitment for key pancreatic cancer trial

Trump chides Powell as Goldman call for calm. The RBA must be nervous

Week 27 Wrap: 40% China tariffs?; ASX +10% FY25; US Amazon price spike

Listen: HotCopper Wire Podcast 016 – FY25 ended up not so bad... but Trump unpause is coming

HotCopper Highlights, Week 27: G8 scalped, Domino’s drops the box, Gemlife brief hype & more

First 34 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

They are slaughtering BTG in the dose sales and consultant Comms...

Top Stories

Is Domino's a steal after -25% plunge?

Inside the Depths of Panasqueira: A Legacy Carved in Rock

New Murchison Gold blasts off at Crown Prince as 'better than expected' results return

Tourism Holdings says Liberation Day tariffs smashed US RV demand

Kula picks up unexplored niobium play in Malawi, with surface samples logged

OncoSil wraps up recruitment for key pancreatic cancer trial

Trump chides Powell as Goldman call for calm. The RBA must be nervous

Week 27 Wrap: 40% China tariffs?; ASX +10% FY25; US Amazon price spike

Listen: HotCopper Wire Podcast 016 – FY25 ended up not so bad... but Trump unpause is coming

HotCopper Highlights, Week 27: G8 scalped, Domino’s drops the box, Gemlife brief hype & more

Featured News